<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Neurosci.</journal-id>
<journal-title>Frontiers in Molecular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5099</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnmol.2021.753500</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Neuroscience</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Meeting of the Portuguese Society for Neurosciences SPN2019</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Di&#x000F3;genes</surname> <given-names>Maria Jos&#x000E9;</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/30788/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Guimas Almeida</surname> <given-names>Cl&#x000E1;udia</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/356793/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Xapelli</surname> <given-names>Sara</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/129383/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Faculdade de Medicina, Instituto de Medicina Molecular Jo&#x000E3;o Lobo Antunes, Universidade de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<aff id="aff2"><sup>2</sup><institution>Faculdade de Medicina, Instituto de Farmacologia e Neuroci&#x000EA;ncias, Universidade de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<aff id="aff3"><sup>3</sup><institution>iNOVA4Health, Chronic Diseases Research Center (CEDOC), NOVA Medical School (NMS), Universidade Nova de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Jean-Marc Taymans, Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale (INSERM), France</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Gary Leo Dunbar, Central Michigan University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Sara Xapelli <email>sxapelli&#x00040;medicina.ulisboa.pt</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Molecular Signalling and Pathways, a section of the journal Frontiers in Molecular Neuroscience</p></fn></author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>14</volume>
<elocation-id>753500</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>09</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2021 Di&#x000F3;genes, Guimas Almeida and Xapelli.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Di&#x000F3;genes, Guimas Almeida and Xapelli</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/9668/meeting-of-the-portuguese-society-for-neurosciences-spn2019" ext-link-type="uri">Editorial on the Research Topic <article-title>Meeting of the Portuguese Society for Neurosciences SPN2019</article-title></related-article>
<kwd-group>
<kwd>neurodevelopment</kwd>
<kwd>neurodegeneration</kwd>
<kwd>glia and neuroinflammation</kwd>
<kwd>drug and addiction</kwd>
<kwd>sensory processing</kwd>
<kwd>rare disorders</kwd>
<kwd>cellular and molecular neurosciences</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="1047"/>
</counts>
</article-meta>
</front>
<body>
<p>The Portuguese Society for Neuroscience meeting (SPN2019) was held in Lisbon from 30th May to 1st June, 2019. The main purpose of this meeting was to promote and develop research in Neurosciences. This interaction took place in a privileged way at this meeting and brought together the vibrant Portuguese Neuroscience community that significantly advances this defying area.</p>
<p>This Research Topic comprises nine manuscripts covering some of the work presented at SPN2019 and hot topics in neurosciences: neurodevelopment; cellular and molecular neurosciences; neurodegeneration; glia and neuroinflammation; drug and addiction; sensory processing; and rare disorders.</p>
<p>In a brief Research Report, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2020.00119">Miranda et al.</ext-link> show that cannabidiol, &#x00394;9-tetrahydrocannabinol, and two synthetic cannabinoids (THJ-018 and EG-018) profoundly impact, from toxicity to precocity, developing neurons, highlighting the negative effect of prenatal exposure to natural and synthetic cannabinoids.</p>
<p>A brief Research Report by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2020.00146">Neiva et al.</ext-link> shows that methylprednisolone differentially affects GABA and glutamate release from rat hippocampal nerve terminals <italic>via</italic> fast non-genomic mechanisms putatively involving the activation of membrane-bound corticosteroid receptors.</p>
<p>Original Research by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnins.2020.00614">Sa de Almeida et al.</ext-link> reveals that microglial Sirtuin 2 (Sirt2) prevents NMDA-mediated excitotoxicity in hippocampal slices in response to an inflammatory signal. Overall, the data suggest a key-protective role for microglial Sirt2 in amnesic deficits associated with neuroinflammation.</p>
<p>Original Research by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2020.00111">Fonteles et al.</ext-link> supports that antagonists of ATP receptors P2X7 are protective of dyskinesia induced by dopamine replacement therapy in a Parkinson&#x00027;s disease rat model. These findings suggest P2X7 antagonists as novel candidate anti-dyskinesia drugs.</p>
<p>Original Research by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnins.2019.01413">Costa-Pereira et al.</ext-link> describes an enhancement of the descending noradrenergic pain control system due to neuropathy induced by cancer chemotherapy. The authors suggest that potentiation of the antinociception mediated by alpha2-adrenoreceptors may be a therapeutic opportunity.</p>
<p>Original Research by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnmol.2020.00157">Fabricio de Sousa et al.</ext-link> shows that the cerebellum is vulnerable to metabolic changes due to ultra-endurance racer. High-volume training in rodents induced cerebellar oxidative and inflammatory status and impaired astrocyte reactivity.</p>
<p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fnins.2019.00680">Mouro et al.</ext-link> reviewed the recent evidence concerning metabolic, synaptic, functional, and molecular dysfunctions occurring in Rett syndrome. From modulators of GABAergic signaling to cannabinoids and the ketogenic diet, cleverly exploiting the metabolic features of this disease, an ample bulk of evidence has been gathered, creating a plethora of research lines to be followed in the future.</p>
<p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2020.00072">Perdig&#x000E3;o et al.</ext-link> reviewed the intracellular trafficking mechanisms of synaptic dysfunction in Alzheimer&#x00027;s disease. They described that in early and late-onset familial Alzheimer&#x00027;s disease the earliest synaptic dysfunctions are characterized by disruptions of the presynaptic vesicle exo- and endocytosis and postsynaptic glutamate receptor endocytosis. While in early-onset familial Alzheimer&#x00027;s disease, synapse dysfunction seems to be triggered by A&#x003B2;, in late-onset Alzheimer&#x00027;s disease, there might be a direct synaptic disruption by late-onset Alzheimer&#x00027;s disease trafficking genes, requiring further research.</p>
<p>The mini-review by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2019.00357">Gon&#x000E7;alves-Ribeiro et al.</ext-link> discussed the role of the increase in glutamate uptake on hippocampal long-term potentiation and depression beyond excitotoxicity.</p>
<p>Overall, this Research Topic compiling both original and review papers shows the diversity in the neuroscience field ranging from <italic>in vitro</italic> to <italic>in vivo</italic> approaches, including rare to common disorders, neurodevelopment to aging, and molecular to behavioral tests. We hope this collection of articles will be highly attractive to the international neuroscience community.</p>
<sec id="s1">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s2">
<title>Publisher&#x00027;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ack><p>The authors would like to thank the following organizations for their funding: MD has been supported by Funda&#x000E7;&#x000E3;o para a Ci&#x000EA;ncia e Tecnologia (FCT) Portugal (PTDC/MED-NEU/31929/2017) and Santa Casa da Miseric&#x000F3;rdia de Lisboa (MB37-2017). The Almeida Lab has been supported by FCT (JPCOFUND/0004/2015); Alzheimer&#x00027;s Association Research Grant (AARG-19-618007); Maratona da Sa&#x000FA;de; iNOVA4Health (UID/Multi/04462/2019), a program financially supported by FCT/Minist&#x000E9;rio da Educa&#x000E7;&#x000E3;o e Ci&#x000EA;ncia, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement. CG salary has been supported by FCT (CEECIND/00410/2017). SX has been supported by FCT (IF/01227/2015).</p>
</ack> 
</back>
</article>